Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proactive safety surveillance.

E A Bortnichak1, R P Wise, M E Salive

  • 1Berlex Laboratories, Inc, Corporate Epidemiology & Public Health Evaluations, Montville, NJ, USA. ed.bortnichak@us.sanofi.com

Pharmacoepidemiology and Drug Safety
|August 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

urf13-T of T cytoplasm maize mitochondria encodes a 13 kD polypeptide.

Plant molecular biology·2013
Same author

Mapping complementary genes in maize: positioning the rf1 and rf2 nuclear-fertility restorer loci of Texas (T) cytoplasm relative to RFLP and visible markers.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Same author

A linkage map of diploid Avena based on RFLP loci and a locus conferring resistance to nine isolates of Puccinia coronata var. 'avenae'.

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Same author

Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics.

Clinical pharmacology and therapeutics·2007
Same author

Epidemiologists and adverse event data--a challenge to the field.

Pharmacoepidemiology and drug safety·2004
Same author

The epidemiology of fatalities reported to the vaccine adverse event reporting system 1990-1997.

Pharmacoepidemiology and drug safety·2002

Enhancing medical product safety surveillance requires proactive strategies beyond spontaneous side effect reports. Data-driven methods and non-spontaneous data sources can uncover hidden risks and improve signal detection for better patient outcomes.

Area of Science:

  • Pharmacovigilance and Health Informatics
  • Medical Product Safety Surveillance
  • Data-Driven Risk Management

Background:

  • Health information systems offer opportunities to improve postmarketing safety surveillance of medical products.
  • Current methods rely heavily on spontaneous suspected side effect reports, which have limitations in detecting unsuspected risks.
  • Proactive strategies are needed to enhance the quality of safety data and signal detection.

Purpose of the Study:

  • To explore proactive methods for improving postmarketing safety surveillance.
  • To identify data-driven techniques for uncovering hidden safety signals and associations.
  • To emphasize the importance of non-spontaneous data for hypothesis generation and testing.

Main Methods:

  • Adaptation of techniques from industrial quality control and other disciplines.

Related Experiment Videos

  • Application of data-driven methods such as exploratory analysis, control charts, and time series modeling.
  • Systematic epidemiologic evaluation of questions and concerns using non-spontaneous data.

    • Main Results:

    • Data-driven techniques can sift through accumulated data to identify new product hazards or refine understanding of known side effects.
    • Proactive methods, including the use of non-spontaneous data, can supplement spontaneous reports for more robust safety surveillance.
    • Signals from any source require independent verification to confirm potential hazards.

    Conclusions:

    • Integrating proactive, data-driven approaches with traditional surveillance enhances the detection of medical product safety issues.
    • Utilizing diverse data sources and advanced analytical methods is crucial for comprehensive postmarketing surveillance.
    • Continuous improvement in safety surveillance strategies is essential for ensuring medical product safety and protecting public health.